TY  - JOUR 
AU  - Borrero-Palacios, A
AU  - Cebrian, A
AU  - Gomez Del Pulgar, M T
AU  - Garcia-Carbonero, R
AU  - Garcia-Alfonso, P
AU  - Aranda, E
AU  - Elez, E
AU  - Lopez-Lopez, R
AU  - Cervantes, A
AU  - Valladares Ayerbes, Manuel
AU  - Nadal, C
AU  - Vieitez, J M
AU  - Guillen-Ponce, C
AU  - Rodriguez, J
AU  - Hernandez, I
AU  - Garcia, J L
AU  - Vega-Bravo, R
AU  - Puime-Otin, A
AU  - Martinez-Useros, J
AU  - Del Puerto-Nevado, L
AU  - Rincon, R
AU  - Rodriguez-Remirez, M
AU  - Rojo, F
AU  - Garcia-Foncillas, J
PY  - 2019
SN  - 2045-2322
UR  - http://hdl.handle.net/20.500.11940/15950
AB  - Cetuximab is a standard-of-care treatment for RAS wild-type metastatic colorectal cancer (mCRC) but not for those harbor a KRAS mutation since MAPK pathway is constitutively activated. Nevertheless, cetuximab also exerts its effect by its...
LA  - eng
KW  - Adult
KW  - Middle Aged
KW  - Humans
KW  - Genes
KW  - Treatment Outcome
KW  - Drug Resistance
KW  - Prospective Studies
KW  - Proto-Oncogene Proteins p21(ras)
KW  - Aged
KW  - Colorectal Neoplasms
KW  - Antineoplastic Agents
TI  - Combination of KIR2DS4 and FcgammaRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
DO  - 10.1038/s41598-019-39291-2
T2  - Scientific Reports
KW  - CHUAC
VL  - 9
ER  -